Kein Fortschreiten einer Adalimumab-induzierten Lungensarkoidose unter Etanercept

J. H. Jung; J. H. Kim; Gwan Gyu Song

doi:10.1007/s00393-016-0262-4

Kein Fortschreiten einer Adalimumab-induzierten Lungensarkoidose unter Etanercept

Translated title of the contribution: Adalimumab-induced pulmonary sarcoidosis not progressing upon treatment with etanercept

J. H. Jung, J. H. Kim, Gwan Gyu Song

Research output: Contribution to journal › Article › peer-review

7 Citations (Scopus)

Abstract

Tumor necrosis factor alpha (TNF-α) inhibitors effectively treat sarcoidosis, but can, paradoxically, induce sarcoidosis. The TNF-α inhibitor etanercept is most commonly associated with paradoxical sarcoidosis, which has previously been reported to be resolved by adalimumab. However, we describe the case of a patient with ankylosing spondylitis and adalimumab-induced sarcoidosis not aggravated by switching to etanercept, thus indicating that etanercept could be a treatment option for patients who develop paradoxical sarcoid-like reactions after treatment with other TNF-α inhibitors.

Translated title of the contribution	Adalimumab-induced pulmonary sarcoidosis not progressing upon treatment with etanercept
Original language	German
Pages (from-to)	372-374
Number of pages	3
Journal	Zeitschrift fur Rheumatologie
Volume	76
Issue number	4
DOIs	https://doi.org/10.1007/s00393-016-0262-4
Publication status	Published - 2017 May 1

Keywords

Adalimumab
Etanercept
Paradoxical response
Pulmonary sarcoidosis
Tumor necrosis factor-α

ASJC Scopus subject areas

Rheumatology

Access to Document

10.1007/s00393-016-0262-4

Cite this

@article{123c5839d4ad4fcab2f7a089dd2cf253,

title = "Kein Fortschreiten einer Adalimumab-induzierten Lungensarkoidose unter Etanercept",

abstract = "Tumor necrosis factor alpha (TNF-α) inhibitors effectively treat sarcoidosis, but can, paradoxically, induce sarcoidosis. The TNF-α inhibitor etanercept is most commonly associated with paradoxical sarcoidosis, which has previously been reported to be resolved by adalimumab. However, we describe the case of a patient with ankylosing spondylitis and adalimumab-induced sarcoidosis not aggravated by switching to etanercept, thus indicating that etanercept could be a treatment option for patients who develop paradoxical sarcoid-like reactions after treatment with other TNF-α inhibitors.",

keywords = "Adalimumab, Etanercept, Paradoxical response, Pulmonary sarcoidosis, Tumor necrosis factor-α",

author = "Jung, {J. H.} and Kim, {J. H.} and Song, {Gwan Gyu}",

year = "2017",

month = may,

day = "1",

doi = "10.1007/s00393-016-0262-4",

language = "German",

volume = "76",

pages = "372--374",

journal = "Zeitschrift fur Rheumatologie",

issn = "0340-1855",

publisher = "D. Steinkopff-Verlag",

number = "4",

}

TY - JOUR

T1 - Kein Fortschreiten einer Adalimumab-induzierten Lungensarkoidose unter Etanercept

AU - Jung, J. H.

AU - Kim, J. H.

AU - Song, Gwan Gyu

PY - 2017/5/1

Y1 - 2017/5/1

N2 - Tumor necrosis factor alpha (TNF-α) inhibitors effectively treat sarcoidosis, but can, paradoxically, induce sarcoidosis. The TNF-α inhibitor etanercept is most commonly associated with paradoxical sarcoidosis, which has previously been reported to be resolved by adalimumab. However, we describe the case of a patient with ankylosing spondylitis and adalimumab-induced sarcoidosis not aggravated by switching to etanercept, thus indicating that etanercept could be a treatment option for patients who develop paradoxical sarcoid-like reactions after treatment with other TNF-α inhibitors.

AB - Tumor necrosis factor alpha (TNF-α) inhibitors effectively treat sarcoidosis, but can, paradoxically, induce sarcoidosis. The TNF-α inhibitor etanercept is most commonly associated with paradoxical sarcoidosis, which has previously been reported to be resolved by adalimumab. However, we describe the case of a patient with ankylosing spondylitis and adalimumab-induced sarcoidosis not aggravated by switching to etanercept, thus indicating that etanercept could be a treatment option for patients who develop paradoxical sarcoid-like reactions after treatment with other TNF-α inhibitors.

KW - Adalimumab

KW - Etanercept

KW - Paradoxical response

KW - Pulmonary sarcoidosis

KW - Tumor necrosis factor-α

UR - http://www.scopus.com/inward/record.url?scp=85010809781&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85010809781&partnerID=8YFLogxK

U2 - 10.1007/s00393-016-0262-4

DO - 10.1007/s00393-016-0262-4

M3 - Article

C2 - 28124746

AN - SCOPUS:85010809781

SN - 0340-1855

VL - 76

SP - 372

EP - 374

JO - Zeitschrift fur Rheumatologie

JF - Zeitschrift fur Rheumatologie

IS - 4

ER -

Kein Fortschreiten einer Adalimumab-induzierten Lungensarkoidose unter Etanercept

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this